Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 279

1.

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial.

Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush AI.

Biol Psychiatry. 2008 Sep 1;64(5):361-8. doi: 10.1016/j.biopsych.2008.03.004. Epub 2008 Apr 23.

PMID:
18436195
2.

Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.

Olié JP, Spina E, Murray S, Yang R.

Int Clin Psychopharmacol. 2006 May;21(3):143-51.

PMID:
16528136
3.

N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial.

Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI.

Biol Psychiatry. 2008 Sep 15;64(6):468-75. doi: 10.1016/j.biopsych.2008.04.022. Epub 2008 Jun 5.

PMID:
18534556
4.

Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.

Casey DE, Sands EE, Heisterberg J, Yang HM.

Psychopharmacology (Berl). 2008 Oct;200(3):317-31. doi: 10.1007/s00213-008-1207-7. Epub 2008 Jul 4.

PMID:
18597078
5.

The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.

Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y.

CNS Drugs. 2009;23(7):615-25. doi: 10.2165/00023210-200923070-00006.

PMID:
19552488
6.
7.

Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial.

Iancu I, Tschernihovsky E, Bodner E, Piconne AS, Lowengrub K.

Psychiatry Res. 2010 Aug 30;179(1):19-23. doi: 10.1016/j.psychres.2010.04.035. Epub 2010 May 15.

PMID:
20472299
8.

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.

Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE.

Arch Gen Psychiatry. 2005 Nov;62(11):1196-204.

PMID:
16275807
9.

A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia.

Lee MS, Kim YK, Lee SK, Suh KY.

J Clin Psychopharmacol. 1998 Oct;18(5):399-403.

PMID:
9790158
10.

Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study.

Lerner V, Bergman J, Statsenko N, Miodownik C.

J Clin Psychiatry. 2004 Nov;65(11):1550-4.

PMID:
15554771
11.

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.

Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A.

J Clin Psychiatry. 2009 Jun;70(6):829-36. doi: 10.4088/JCP.08m04905. Epub 2009 Jun 2.

PMID:
19497249
12.

Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.

Kane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD.

J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S29-35. doi: 10.1097/JCP.0b013e318169cca7.

PMID:
18334910
13.

A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia.

Pierre JM, Peloian JH, Wirshing DA, Wirshing WC, Marder SR.

J Clin Psychiatry. 2007 May;68(5):705-10.

PMID:
17503979
14.

Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.

Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M.

J Clin Psychiatry. 2008 May;69(5):817-29.

PMID:
18466043
15.

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.

Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD.

J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S20-8. doi: 10.1097/JCP.0b013e318169d4ce.

PMID:
18334909
17.

Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.

Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A.

Biol Psychiatry. 2007 Dec 15;62(12):1363-70. Epub 2007 Jun 28.

PMID:
17601495
18.

Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.

Ratner Y, Gibel A, Yorkov V, Ritsner MS.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1;31(7):1401-9. Epub 2007 Jun 21.

PMID:
17669574
19.

Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.

Lawson WB, Herman BK, Loebel A, Lazariciu I, Malik M.

CNS Spectr. 2009 Sep;14(9):478-86.

PMID:
19890230
20.

Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.

Akhondzadeh S, Safarcherati A, Amini H.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):253-9. Epub 2004 Dec 28.

PMID:
15694232

Supplemental Content

Support Center